Debbie Rigby rounds up the latest in research news
Analysis of data from the Women’s Health Initiative shows 10 to 13 years of bisphosphonate use is associated with a 29% higher risk of any clinical fracture than 2 years of use in older women. However the association was not statistically signiﬁcant for hip, clinical vertebral, or wrist fractures. On average participants were 80 years old and were followed for 3.7 ± 1.2 years.
J Am Geriatr Soc 2017;65:In press
A systematic review and network meta-analysis of 42 trials, including 144,220 patients, suggests that reducing SBP to levels below currently recommended targets significantly reduces the risk of cardiovascular disease and all-cause mortality. These findings support more intensive control of SBP among adults with hypertension.
JAMA Cardiol. Published online May 31, 2017.
The 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis recommends treating only with calcium and vitamin D in adults at low fracture risk, and treating adults at moderate-to-high fracture risk with calcium and vitamin D plus an additional osteoporosis medication (oral bisphosphonate preferred). The guidelines also make recommendations for special populations, including children, people with organ transplants, women of childbearing potential, and people receiving very high-dose glucocorticoid treatment.
Arthritis & Rheumatology 2017
A systematic review and meta-analysis of randomised trials has concluded that incretin based treatments, including dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, do not increase all cause mortality in patients with type 2 diabetes.